CRISPR Therapeutics AG Annual Net Cash Provided by (Used in) Investing Activities in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Summary
CRISPR Therapeutics AG quarterly/annual Net Cash Provided by (Used in) Investing Activities history and growth rate from 2016 to 2023.
  • CRISPR Therapeutics AG Net Cash Provided by (Used in) Investing Activities for the quarter ending March 31, 2024 was -$97.8M, a 183% decline year-over-year.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Investing Activities for 2023 was $375M.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Investing Activities for 2022 was -$259M, a 75% increase from 2021.
  • CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Investing Activities for 2021 was -$1.04B, a 91.3% decline from 2020.
Net Cash Provided by (Used in) Investing Activities, Annual (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $375M +$633M Jan 1, 2023 Dec 31, 2023 10-K 2024-02-21
2022 -$259M +$777M +75% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-21
2021 -$1.04B -$494M -91.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$541M -$542M -40943% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $1.33M +$4.1M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$2.77M +$5.54M +66.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$8.31M -$40.2M -126% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 $31.9M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.